drugset
drugset / Trial / NCT03892902

A Clinical Study to Assess Next-day Driving Performance Following Administration of ACT-541468 in Middle-aged and Elderly Subjects

NCT03892902 ↗

Phase 1 Completed 56 enrolled Idorsia Pharmaceuticals Ltd.
RandomizedCrossoverQuadruple-blindOther

Summary

A clinical study to assess next-day driving performance following evening administrations of ACT-541468 in middle-aged and elderly subjects

Timeline

Start
2019-03-25
Primary completion
2019-10-10
Completion
2019-10-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Daridorexant Small molecule 50 mg Oral
Subject Daridorexant Small molecule 100 mg Oral
Subject Zopiclone Small molecule 7.5 mg —

Indications

No indication recorded.